Qiagen aims to develop new tests to target blood cancer patients who would benefit most from a particular treatment that hits a specific gene mutation. The plan could lead to new companion diagnostic tests for related drugs now under development.
Qiagen received FDA approval on June 24 under a full PMA for an assay that monitors the viral load of cytomegalovirus (CMV), a common virus that can be fatal to weakened immune systems, in organ transplant patients.
Qiagen and Eli Lilly have joined forces for their fourth companion diagnostics project, building on the momentum of past collaborations to develop assay panels for cancer.
Qiagen and Eli Lilly have clicked well enough in previous companion diagnostics development projects that they're signing up for a fourth go-around.
Qiagen gained FDA approval for a companion diagnostic test that will help spot patients with metastatic colorectal cancer who might benefit most from Amgen's drug Vectibix. The regulatory milestone represents another advance in the Dutch company's growing focus on personalized medicine.
Qiagen reported adjusted net income of $53.7 million on sales of $317.4 million in the first quarter. Net sales rose 4.5% year-over-year, and net income was up 11.6% at constant exchange rates.
Molecular diagnostics company Qiagen will invest $10 million to build out manufacturing capabilities at its Germantown, MD, campus by early 2015, focusing on products for women's health and infectious disease.
Qiagen snatched up a biomarker from an Austrian research group that will aid in the development of a test designed to better diagnose rare blood disorders.
Qiagen has started marketing a next-generation tuberculosis blood test in China, four months after winning regulatory approval there in what will be a key market for the company in the months ahead.
Dutch molecular diagnostics conglomerate Qiagen launched its new human papillomavirus test in India for women in areas with limited healthcare infrastructure. The company is touting the careHPV test as the first designed specifically with this patient group in mind.